48 results on '"Pérez-Corral, Ana"'
Search Results
2. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
3. Red Blood Cell Transfusion after Postpartum Hemorrhage: Clinical Variables Associated with Lack of Postpartum Hemorrhage Etiology Identification
4. Bone marrow transplant in patients with sickle cell anaemia. Experience in one centre
5. Trasplante de médula ósea en pacientes con anemia falciforme. Experiencia en un centro
6. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.
7. Transient hemolysis due to anti‐D and anti‐A1 produced by engrafted donorʼs lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation
8. Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic Stem Cell Transplantation: Correlation with Flow Cytometry and Chimerism
9. Clinical grade production of IL ‐15 stimulated NK cells for early infusion in adult AML patients undergoing haploidentical stem cell transplantation with post‐transplant cyclophosphamide
10. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel
11. Day 14 Measurable Residual Disease As a Predictor of Post-Induction Response in Patients with Acute Myeloid Leukemia
12. Patients with Acute Myeloid Leukemia on Non-Intensive Therapy: Applicability of the European Leukemia Net Risk Classification
13. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation
14. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Responses
15. International Forum on Transfusion Practices in Haematopoietic Stem‐Cell Transplantation: Summary
16. Application of the French TMA Reference Center Score and the mortality in TTP Score in de novo and relapsed episodes of acquired thrombotic thrombocytopenic purpura at a tertiary care facility in Spain
17. Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: Experience from a single center
18. Mononuclear cell collection for extracorporeal photopheresis by using the “ off‐line ” system: A comparative study between COBE Spectra and Spectra Optia devices
19. Impact of Early Immune Reconstitution after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide
20. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications
21. Transient hemolysis due to anti-D and anti-A1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation.
22. Impact of Minimal Residual Disease and Chimerism Monitoring at Different Timepoints after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
23. Transient hemolysis due to anti‐D and anti‐A 1 produced by engrafted donor's lymphocytes after allogeneic unmanipulated haploidentical hematopoietic stem cell transplantation
24. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome. Is it feasible?
25. Myeloablative Conditioning Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PTCy) As GvHD Prophylaxis in High Risk Leukemias/Myelosdysplastic Syndromes (MDS): Geth Experience
26. Mononuclear cell collection for extracorporeal photopheresis by using the "off‐line" system: A comparative study between COBE Spectra and Spectra Optia devices.
27. A Real-World Analysis of Immune Thrombotic Thrombocytopenic Purpura: Comparing Clinical Outcomes of Conventional Treatment Vs Addition of Caplacizumab, a Single-Center Experience
28. Busulfan‐based myeloablative conditioning regimens for haploidentical transplantation in high‐risk acute leukemias and myelodysplastic syndromes.
29. Multicenter comparison of CD34+ myeloid cell count by flow cytometry in low‐risk myelodysplastic syndrome. Is it feasible?
30. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation
31. Myeloablative Haploidentical Stem Cell Transplantation (MAC-HAPLO) with Post-Transplant Cyclophosphamide (PT-CY) As GVHD Prophylaxis in High Risk Leukemias/Myelosdisplastic Syndromes (MDS)
32. Evaluation of Donor KIR2DL1 Allelic Polymorphism in the Setting of T-Cell Repleted Haploidentical Transplantation
33. Linear Relationship Between Lymphocyte Subpopulations Counts in Peripheral Blood and Buffy-Coat during Extracorporeal Photopheresis in Patients with Graft-Versus-Hot-Disease Using an Off-Line System
34. Differences in Natural Killer(NK) Reconstitution Between Unmanipulated Haploidentical and HLA Identical Stem Cell Transplantation and Relationship with Citomegalovirus and Graft Versus Host Disease (GVHD). Experience in One Centre in 22 Patients.
35. Mobilisation of PBSC for Allogenic Transplantation By the Use of G-CSF Biosimilar Zarzio® in Healthy Donors
36. Diagnostic screening of paroxysmal nocturnal hemoglobinuria: Prospective multicentric evaluation of the current medical indications.
37. Early Evaluation Of Natural Killer Cell Reconstitution Following Unmanipulated Haploidentical Transplantation Compared With HLA-Identical Sibling Transplantation
38. Haploidentical Stem Cell Transplantation (HAPLO-HSCT) With High Dose Cyclophosphamide Post-Transplant (HD-CY) As Gvhd Prophylaxis In High Risk Hematologic Malignancies: Multicentric Spanish Experience
39. The Challenge Of Quantifying CD34+ Myeloid Cells In Myelodysplastic Syndromes With Less Than 5% Bone Marrow Blasts. Reproducibility Among 6 Flow Cytometry Observers
40. Early and Favourable Immune Reconstitution After Unmanipulated Haploidentical Stem Cell Transplantation With High Dose Post-Transplant Cyclophosphamide Regardless Intensity Of Conditioning Regimen
41. Haploidentical Transplantation (HAPLO) with Post-Transplant High-Dose Cyclophosphamide for Graft Vs Host Disease (GVHD) Prevention in the Treatment of High Risk Hematological Neoplasms
42. Value of Pretransplantation Minimal Residual Disease in Acute Myeloid Leukemia and Myeloablative Hematopoietic Cell Transplantation.
43. Interlaboratory Variation in CD34+ Cell Quantification in Low Risk Myelodysplastic Syndromes
44. Influence of CD34+ and CD3+ Graft Content on Gvhd Development after Haploidentical Allogeneic Transplantation with Post-Transplant Cyclophosphamide
45. Successful Outcome of Two Pregnancies in a Woman with Bernard Soulier Syndrome
46. Antithrombotic Therapy in Non-Neoplastic Chronic Portal Venous Thrombosis in Cirrhosis: Recanalization and Liver Function Evaluation,
47. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
48. Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.